63 174

Cited 0 times in

Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk

DC Field Value Language
dc.contributor.author곡지호-
dc.contributor.author배숭준-
dc.contributor.author안성귀-
dc.contributor.author정준-
dc.contributor.author지정환-
dc.contributor.author차윤진-
dc.date.accessioned2021-12-28T17:01:05Z-
dc.date.available2021-12-28T17:01:05Z-
dc.date.issued2021-08-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/186895-
dc.description.abstractWe assessed the impact of 21-gene Recurrence Score (RS) assay on chemotherapy decision-making according to binary clinical risk stratification in patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. We included patients with tumors measuring 1-5 cm, N0-1, and HR+/HER2- breast cancer who underwent surgery followed by adjuvant treatment. The clinical risk was determined by a modified version of Adjuvant! Online. We performed propensity score matching (PSM) according to the application of 21-gene RS separately in the low and high clinical risk groups. Before PSM, 342 (39.0%) of 878 patients were classified as having high clinical risk. In the high clinical risk group, 21-gene RS showed a significantly reduced chemotherapy rate of 39.3%, without increasing the recurrence. After PSM, the 21-gene RS application significantly reduced chemotherapy rate by 34.0% in 200 patients with high clinical risk (21-gene RS application, 32.0% vs. no 21-gene RS application, 66.0%, p < 0.001). There was also no significant difference in RFS according to 21-gene RS status in the high clinical risk group (log-rank test, p = 0.467). These results support the usefulness of the 21-gene RS to reduce the chemotherapy rate without adversely affecting prognosis in a high clinical risk group.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherMDPI-
dc.relation.isPartOfCANCERS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleApplication of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorSoong June Bae-
dc.contributor.googleauthorSung Gwe Ahn-
dc.contributor.googleauthorJung Hwan Ji-
dc.contributor.googleauthorChihhao Chu-
dc.contributor.googleauthorDooreh Kim-
dc.contributor.googleauthorJanghee Lee-
dc.contributor.googleauthorYoon Jin Cha-
dc.contributor.googleauthorJoon Jeong-
dc.identifier.doi10.3390/cancers13164003-
dc.contributor.localIdA06143-
dc.contributor.localIdA05345-
dc.contributor.localIdA02231-
dc.contributor.localIdA03727-
dc.contributor.localIdA06110-
dc.contributor.localIdA04001-
dc.relation.journalcodeJ03449-
dc.identifier.eissn2072-6694-
dc.identifier.pmid34439158-
dc.subject.keyword21-gene recurrence score-
dc.subject.keywordadjuvant treatment-
dc.subject.keywordbreast neoplasms-
dc.subject.keywordchemotherapy-
dc.subject.keywordclinical risk-
dc.contributor.alternativeNameChu, Chihhao-
dc.contributor.affiliatedAuthor곡지호-
dc.contributor.affiliatedAuthor배숭준-
dc.contributor.affiliatedAuthor안성귀-
dc.contributor.affiliatedAuthor정준-
dc.contributor.affiliatedAuthor지정환-
dc.contributor.affiliatedAuthor차윤진-
dc.citation.volume13-
dc.citation.number16-
dc.citation.startPage4003-
dc.identifier.bibliographicCitationCANCERS, Vol.13(16) : 4003, 2021-08-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.